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Abstract
Background:   Sulfasalazine is a widely used anti-inflammatory agent in the treatment of
inflammatory bowel disease and several rheumatological disorders. Although as many as 20% of
treated patients may experience reversible, dose-dependent side effects, less frequent but
potentially severe, systemic reactions have also been reported.
Case Presentation:  A severe systemic reaction to sulfasalazine developed in a 21-year old
female with rheumatoid arthritis characterized by eosinophilia, granulomatous enteritis and
myelotoxicity, cholestatic hepatitis, and seizures. The clinical course and management of this
patient are presented as well as a review of the incidence and outcome of severe systemic reactions
to sulfasalazine.
Conclusions:  Granulomatous myelotoxicity and enteritis developed in a 21 year old female
within 3 weeks of initiating sulfasalazine for rheumatoid arthritis. Following a short course of
corticosteroids, the patient had resolution of her cholestatic hepatitis, rash, eosinophilia, and
gastrointestinal symptoms with no residual manifestations at 7 months follow-up. Although severe
reactions to sulfasalazine are rare and unpredictable, practicing physicians should be aware of
unusual clinical presentations of toxicity when prescribing sulfasalazine.
Background
Sulfasalazine (SSZ) is a widely used and highly effective
anti-inflammatory agent in the treatment of Crohn's dis-
ease and ulcerative colitis [1–3]. SSZ is also being used
with increasing frequency in the treatment of various
rheumatolgical disorders [4–7]. SSZ is preferred over
other agents such as gold and penicillamine in rheuma-
tology patients due to its more favorable side effect pro-
file [8–10]. Nonetheless, rash, fever, and dyspepsia
occur in 3% to 20% of treated patients [7,11,12]. These re-
actions are usually dose dependent and improve with
dose reduction or discontinuation [7,12]. However, more
serious but less common side effects have also been re-
ported [13–19]. We now report a severe systemic reac-
tion to SSZ in a 21-year-old female with rheumatoid
arthritis characterized by granulomatous infiltration of
the bone marrow, colon and small bowel as well as chole-
static hepatitis and seizures.
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Case Report
A 21-year old female was diagnosed with polyarticular
rheumatoid arthritis in 1997 and was managed with
naprosyn (Naproxen, Roche Laboratories, Nutley, NJ)
for 4 years. Joint inflammation was well controlled with
hydroxychlorquine (Plaquenil, Sanofi Pharmaceuticals,
New York, NY) from October 1999 thru June 2000 when
hydroxychlorquine was discontinued due to persistent
anemia and a flare in her arthritis despite adequate ther-
apy. The patient was started on iron supplementation
and a 4-week course of low dose prednisone in June/
July 2000. Due to persistent arthritis, sulfasalazine was
initiated on July 28, 2000 at a dose of 500 mg twice dai-
ly, increasing to 1000 mg twice daily. Liver biochemis-
tries were normal immediately before and two weeks
after initiating SSZ. Three weeks after starting SSZ, the
patient developed an erythematous rash over the upper
extremities and trunk that improved with cetirizine
(Zyrtec, Pfizer Inc, New York, NY). She then developed
fatigue, abdominal pain, diarrhea, and night sweats
which lead to hospitalization on 8/29/00 and SSZ was
discontinued. At presentation, serum alkaline phos-
phatase was 923 IU/L, AST 105 IU/L, ALT 143 IU/L, bi-
lirubin 4.3 mg/dl, and WBC was 9.6 k/l with 12%
eosinophils. Over the next six days, she gained 20
pounds in fluid weight and had fevers of 103°F despite
broad spectrum antibiotics. She was transferred on hos-
pital day # 6 to the University of Michigan Medical Cent-
er for further evaluation and management.
The patient reported a prior history of infectious mono-
nucleosis at age 18 and was a non-smoker and consumed
alcohol infrequently. She denied any known drug aller-
gies or prior exposure to sulfa containing medications or
antibiotics. There was no family history of allergy to sulfa
products.
On hospital day #6, the patient appeared toxic with a
temperature of 102°F, pulse 154/min, and blood pres-
sure of 100/58. Scleral icterus was present as well as
deeply jaundiced, edematous skin with a macular, ery-
thematous rash. Non-tender, 1–2 cm lymph nodes were
palpated in the neck, axilla, and groin. There were de-
creased breath sounds with mild bibasilar rales and a hy-
perdynamic precordium. The abdomen was diffusely
tender and distended. Rectal examination revealed
brown hemoccult + stool. Neurologic examination was
unremarkable.
Laboratory studies revealed a WBC count of 44.2 ×  106/
L with 11 % bands, 24% neutrophils, 30% lymphocytes,
12% monocytes, and 22% eosinophils. The WBC and ab-
solute neutrophil count nadired on hospital day # 19 (Ta-
ble 1). Hemoglobin was 9.3 g/dl, platelets 336,000,
reticulocyte count 3.1% and serum ferritin 17 ng/ ml. The
serum alkaline phosphatase was 1002 IU/L, AST 57 IU/
L, ALT 76 IU/L, total bilirubin 6.6 mg/dl, albumin 1.6,
total protein 3.6 g/dl and INR 1.5. Serum fibrinogen was
126 mg/dl and d-dimer levels were elevated at 0.2–0.40
mcg/ ml. Hepatitis A, B, and C serologies and ANA and
ANCA were negative. CT scan of the chest, abdomen, and
pelvis revealed bilateral pleural effusions, splenomegaly,
and axillary, para-aortic, and inguinal lymphadenopa-
thy. Stool Clostridium difficile toxin B was negative. Be-
cause of her persistent diarrhea, hypoalbuminemia, and
anemia, an upper endoscopy and flexible sigmoidoscopy
were performed on hospital day # 8 to exclude a protein
losing enteropathy. Although both studies were endo-
scopically normal, histopathology of random mucosal bi-
opsies revealed characteristic features of Crohn's disease
with granulomas in the colon and erosive duodenitis
with a single granuloma in the small bowel (Figure 1).
Anti-gliadin and anti-endomysial antibodies were nega-
tive. On hospital day # 9, a bone marrow biopsy revealed
marked eosinophilia and multiple, non-caseating granu-
lomas. Flow cytometry of the bone marrow and periph-
eral blood revealed no evidence of malignancy. AFB and
fungal stains of the gastrointestinal and bone marrow bi-
opsies were negative as were cultures of the bone marrow
6 weeks later. A PPD and candida control were both non-
reactive.
Given the suspicion of a systemic drug reaction as the eti-
ology of her illness, the patient was given high dose intra-
venous steroids for three days starting on hospital day #
14 followed by a prednisone taper. Within 24 hours, the
patient had a rapid improvement of her diarrheal symp-
toms followed by resolution of her peripheral edema and
lymphadenopathy. There were also concomitant im-
provements in her hematological and liver profiles (Ta-
ble 1, Figure 2). However, the patient developed
generalized absence seizures on hospital day #20. Cere-
brospinal fluid analysis revealed an isolated increased
WBC of 14 with a normal protein level. An MRI of the
brain with gadolinium contrast identified patchy and ir-
regular signal enhancement in the gray matter of the oc-
cipital poles, frontoparietal regions, and cerebellar
hemispheres. The patient was started on phenytoin and
later changed to oxcarbazepine. At 1 month post-dis-
charge, the patient was markedly improved as her ster-
oid dose was tapered. At 3 months post-discharge, a
repeat upper and lower endoscopy with terminal ileum
intubation and random biopsies were normal. At 7
months after presentation off steroids, the patient had
completely recovered with no evidence of residual hema-
tological, gastrointestinal, or neurological sequelae.
Discussion
Sulfasalazine is a widely used anti-inflammatory agent in
the treatment of Crohn's disease and ulcerative colitisBMC Gastroenterology 2001, 1:8 http://www.biomedcentral.com/1471-230X/1/8
[1–3]. Recent data has demonstrated that SSZ is also safe
and effective in the treatment of rheumatoid arthritis
and other rheumatological disorders [4,5]. Sulfasalazine
is a dimer composed of 5-aminosalicylic acid linked by
an azo bond to sulfapyridine. The anti-inflammatory ac-
tivity of SSZ is due to the 5-aminosalicylic acid compo-
nent while the majority of the adverse side effects have
been attributed to the sulfapyridine moiety [14–16]. Fe-
ver, abdominal pain, and rash may develop in 3% to 20%
of treated patients, but these side effects are usually mild
and improve with dose reduction [7,11,12]. Severe side
effects necessitating SSZ discontinuation occur in less
than 5% of treated patients [11].
Our patient developed a severe systemic illness following
three weeks of SSZ therapy for rheumatoid arthritis. In
retrospect, her clinical presentation with rash, fever, and
lymphadenopathy within 4 weeks of initiating treatment
is consistent with severe SSZ toxicity [17]. However, in
this case and others, it can be difficult to distinguish a se-
Figure 1
A: Medium-power photomicrograph of the colon showing a small epithelioid granuloma (arrow) (Hematoxylin and eosin stain.
B: Low-power photomicrograph of bone marrow showing a hypercellular marrow with an epithelioid granuloma (arrow)
(Hematoxylin and eosin stain).
Table 1: Hematologic parameters
Hospital Day† Total WBC  Absolute Absolute
     Count Neutrophil 
Count
Eosinophil 
Count
-14 6,000 5,000 200
1 9,600 5,000 1,152**
6 45,200 15,500 9,700**
14 10,100 3,800 5,400**
18 5,300 1700 300
19 6,000 1000* 500**
20 5,000 2400 200
40 11,600 9600 200
*Absolute neutropenia (ANC < 1500/ml): ** Absolute eosinophilia 
(AEC > 400/ml) †Day – 14 = Baseline values 2 weeks after starting SSZ 
Day 1 = Admission to Hospital Day 40 = Follow-up after dischargeBMC Gastroenterology 2001, 1:8 http://www.biomedcentral.com/1471-230X/1/8
vere drug reaction from other disease processes such as
infection and malignancy. In our patient's case, a con-
cern of lymphoma was raised in light of her underlying
rheumatoid arthritis as well as prominent lymphadenop-
athy and splenomegaly. In addition, a possible oppor-
tunistic fungal, mycobacterial, or other atypical infection
was raised with the high fevers, low grade DIC, and dis-
seminated granulomas that persisted after SSZ discon-
tinuation. Lastly, Crohn's disease or ulcerative colitis
with extraintestinal manifestations was a possibility with
her severe iron deficiency anemia, diarrhea, and granu-
lomatous enteritis. It was only after extensive evaluation
that a preliminary diagnosis of SSZ drug toxicity was
made. Occult inflammatory bowel disease was not defin-
itively excluded until follow-up endoscopy was repeated
3 months later.
This patient's clinical presentation with multi-organ in-
volvement due to an immunoallergic reaction to SSZ has
not been previously reported. The gastrointestinal mu-
cosal biopsies in this patient demonstrated multiple non-
caseating granulomas with prominent eosinophilia sug-
gestive of Crohn's disease (Figure 1). In addition, the pa-
tient's bone marrow biopsy also demonstrated multiple
non-caseating granulomas and eosinophilia. Although
other systemic illnesses such as untreated tuberculosis,
Q fever, fungal infections, and lymphoma can lead to gas-
trointestinal granuloma, the acute nature of this pa-
tient's symptoms and rapid improvement with steroids
make these causes unlikely. Furthermore, special stains
and studies of the patient's tissues revealed no evidence
of malignancy or infection. To our knowledge, only one
other case of a systemic granulomatous reaction to SSZ
Figure 2
Liver biochemical profile. The patient had a normal serum alkaline phosphatase and bilirubin level 14 days prior to presenta-
tion. The marked intrahepatic cholestasis did not improve until initiation of steroids on day #14. At post-discharge follow-up
on day #40, both the serum alkaline phosphatase and bilirubin had normalized. * = Upper limit of normal
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has been reported which improved within 24 hours of
SSZ discontinuation [18]. In other cases of granuloma-
tous drug reactions, multi-organ involvement with fevers
and eosinophilia have been reported [19,20].
Our patient had severe cholestatic hepatitis with coagu-
lopathy. Although Still's disease can rarely lead to hepat-
ic involvement with cholestatic hepatitis, the prior
history of rheumatoid factor seropositivity and a low se-
rum ferritin level made this diagnosis unlikely [21].
Granulomatous hepatitis with marked elevations in se-
rum alkaline phosphatase and granulomas on liver biop-
sy have been reported in patients with SSZ
hepatotoxicity [22–24]. Although liver tissue was not ob-
tained in our patient, the predominance of serum alka-
line phosphatase and bilirubin level elevations and the
presence of granulomas in other tissues suggest that she
probably had granulomatous hepatitis. The presumed
mechanism of liver injury in SSZ hepatotoxicity is an id-
iosyncratic hypersensitivity response. Both severe hepa-
titis and acute liver failure have been attributed to SSZ
[25–28]. Patients with SSZ hepatotoxicity demonstrate a
prompt recurrence of symptoms upon rechallenge with
SSZ or sulfonamide [15,29–31]. Susceptibility to the tox-
ic effects of SSZ and other sulfonamides may be due to
the interaction of metabolic pathways regulating N-
acetylation and specific detoxification of the metabolites
of the drug [32,33]. However, it remains unclear if genet-
ic differences in drug metabolizing enzyme expression
may increase the risk of SSZ toxicity.
Myelotoxicity in this patient was manifest by leukopenia
and neutropenia (Table 1). SSZ has previously been asso-
ciated with neutropenia with an estimated incidence of
0.04% during the first 30 days of treatment [34]. Bone
marrow biopsy specimens of patients with SSZ induced
agranulocytosis reveal a paucity of myeloid cells but full
recovery typically occurs within 10 days of drug discon-
tinuation [35–37]. Although our patient had adequate
myeloid cells in her bone marrow biopsy, she developed
absolute neutropenia by hospital day #19 that improved
with steroid therapy. SSZ induced agranulocytosis is be-
lieved to be mediated by immunological hypersensitivity
of myeloid precursors [38]. Spontaneous recovery from
SSZ agranulocytosis is frequently seen, although fatali-
ties have been reported and some patients may benefit
from granulocyte macrophage-colony stimulating factor
[39,40].
A final clinical feature of SSZ toxicity in our patient was
the development of seizures. Although this patient had
no known risk factors, the onset of seizures began in
combination with other clinical manifestations of SSZ
toxicity. Interestingly, the MRI demonstrated diffuse
gray matter abnormalities. Although central nervous
system vasculitis due to immune complex deposition or
drug-induced lupus is a possible etiology of seizures in
this patient, there was no evidence of immune complex
deposition elsewhere. Another possibility is that this pa-
tient may have developed CNS granulomas. Seizures
have previously been reported in patients receiving SSZ,
often in the setting of other clinical manifestations of
toxicity [31,41,42]. Although a brain biopsy would be
needed to prove our hypotheses, there is a precedent for
other systemic granulomatous disorders such as sar-
coidosis leading to CNS granuloma formation and sei-
zures [43,44]. Fortunately, this patient has remained
stable with no evidence of a progressive neurological dis-
order 7 months after presentation.
Treatment of severe adverse drug reactions is primarily
supportive once a diagnosis has been established and the
offending agent has been discontinued. However, in this
patient's case with her prominent features of a hypersen-
sitivity reaction and failure to improve after SSZ discon-
tinuation, corticosteroids were administered to hasten
recovery. Fortunately, most of her clinical symptoms
promptly improved after steroids were begun. The use of
steroids in the setting of SSZ toxicity is controversial and
not always effective. In cases of fulminant hepatic failure
and agranulocytosis, several patients have died despite
the use of steroids [27,28,37]. Intravenous immunoglob-
ulin was reported as a successful "rescue" therapy in a
patient with SSZ induced fulminant hepatic failure and
erythroid hypoplasia who had not responded to steroids
[25]. Due to the infrequent occurrence of severe SSZ tox-
icity that does not improve with drug discontinuation, it
is unlikely that randomized controlled trials of steroids
or other interventions will be performed. It appears rea-
sonable to reserve steroids for patients with severe sys-
temic SSZ toxicity that fail to respond to supportive care
following drug discontinuation.
Conclusions
Sulfasalazine is a commonly used and effective medica-
tion in the treatment of inflammatory bowel disease and
various rheumatologic disorders. Side effects usually de-
velop within 3 months of treatment and are frequently
managed with dose adjustments. However, there is a
subset of patients who may develop severe and unusual
systemic side effects. Although rheumatology patients
may be at increased risk of SSZ toxicity compared to IBD
patients, there are no reliable laboratory or clinical pre-
dictors of SSZ toxicity [45]. Therefore, practicing physi-
cians should be aware of the potential for severe,
unexplained granulomatous reactions to SSZ that can
mimic other infectious, malignant, and autoimmune
conditions. Fever, rash, and eosinophilia developing
within 3 months of initiating SSZ should alert the clini-
cian to the possibility of a drug reaction. Patients withBMC Gastroenterology 2001, 1:8 http://www.biomedcentral.com/1471-230X/1/8
SSZ toxicity should avoid exposure to all sulfonamide
containing drugs due to potential cross-reactivity. In ad-
dition, some inflammatory bowel disease patients have
demonstrated cross-reactivity to 5-ASA products [11]. If
severe symptoms do not resolve with SSZ discontinua-
tion, a short course of corticosteroids may be of benefit.
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